Core Viewpoint - On October 9, a total of 11 listed companies had their restricted shares unlocked, with a total market value of approximately 24.303 billion yuan [1] Summary by Category Restricted Share Unlocking - The companies involved in the unlocking of restricted shares include: - Guo Xin Health (000503) with 1.6798 million shares from equity incentive restrictions - Kang Yuan Pharmaceutical (600557) with 315,500 shares from equity incentive restrictions - Sen Te Co., Ltd. (603098) with 270,000 shares from equity incentive restrictions - San Ren Xing (605168) with 165,300 shares from equity incentive restrictions - Hai Liang Data (603138) with 5.6629 million shares from equity incentive restrictions - Tian Yi Medical (301097) with 40.6 million shares from extended lock-up period - Ming Li Da (301268) with 19 million shares from extended lock-up period - Heng Yu Xintong (300965) with 3.51045 million shares from extended lock-up period - Pu Yuan Jing Dian (688337) with 11.8 million shares unlocked - Zhong Fu Shen Ying (688295) with 29.8 million shares unlocked - Chang Guang Hua Xin (688048) with 7.007 million shares unlocked [1]

Group 1 - A total of 13 companies had their restricted shares unlocked on October 9, with a combined unlock volume of 826 million shares, valued at 28.72 billion yuan based on the latest closing prices [1] - Six companies had unlock volumes exceeding 10 million shares, with Zhongfu Shenying, Kangguan Technology, and Puyuan Precision Electronics leading the unlock volumes at 298 million shares, 254 million shares, and 118 million shares respectively [1] - In terms of unlock market value, six companies had unlock values exceeding 100 million yuan, with Zhongfu Shenying, Kangguan Technology, and Changguang Huaxin leading at 8.424 billion yuan, 5.908 billion yuan, and 5.308 billion yuan respectively [1] Group 2 - Six companies had unlock ratios exceeding 10% of their total share capital, with Puyuan Precision Electronics, Hengyu Xintong, and Changguang Huaxin having the highest unlock ratios at 61.0%, 58.51%, and 39.75% respectively [1]

9月29日，普源精电科技股份有限公司(以下简称"普源精电")在港交所提交上市申请，公司上市材料被正式受理，独家保荐人为中信证券。 资料显示，普源精电2022年4月登陆上交所，主营业务为通用电子测量仪器的研发、生产和销售。 据招股书，普源精电是中国领先的电子测量仪器公司，拥有先进的技术实力和遍布全球的庞大版图。根据弗若斯特沙利文的资料，公司是中国最大的电子 测量仪器供货商，按收益计，于2024年在全球排名第八。 财务数据方面，2022年至2024年，普源精电分别实现收入6.31亿元、6.71亿元、7.76亿元，净利润分别为9248.84万元、1.08亿元、9230.31万元，2024年净 利润有所下滑。 有机会获商报君送出的礼品 朋友们千万别错过！ ↓↓↓ 公司毛利率近年来一路提升，由2022年的50.9%升至2024年的54.9%，不过2025年上半年降至51.9%，显示公司盈利能力存在一定压力。 公司的原材料包括IC芯片、电子元件、结构件、印刷电路板、显示器等辅助材料。2022年至2024年及2025年上半年，原材料成本分别占销售成本的 73.9%、72.3%、67.8%及69.0%。普源精电坦言，原材料价 ...

Summary of Key Points Core Viewpoint The article provides an overview of the recent activities in the Hong Kong stock market, highlighting the number of companies that have submitted listing applications, those that have passed the hearing process, and new stocks that have been listed. Group 1: Companies Submitting Listing Applications - A total of 30 companies submitted listing applications to the Hong Kong Stock Exchange during the week from September 29 to October 5 [1] - Notable companies include: - Yantai Lannacheng Biotechnology Co., Ltd., a clinical-stage biotech company focused on radiopharmaceuticals for cancer treatment, reported revenues of approximately 1.027 million RMB for 2023 and a loss of about 112 million RMB [2][3] - XGIMI Technology Co., Ltd., the world's largest consumer-grade projector brand by revenue, reported revenues of approximately 4.22 billion RMB for 2022 and a profit of about 501 million RMB [2][3] - WeDoctor Holdings Limited, a leading digital health service provider in China, reported revenues of 1.368 billion RMB for 2022 and a loss of 909 million RMB [4][5] - Puyuan Precision Electronics Co., Ltd., the largest electronic measurement instrument supplier in China, reported revenues of approximately 631 million RMB for 2022 and a profit of about 92.5 million RMB [5][6] - Shenzhen Huanchuang Technology Co., Ltd., a leader in high-precision spatial perception solutions, reported a market share of over 50% in the laser radar products for robotic vacuum cleaners [6] Group 2: Companies Passing Hearing Process - Four companies passed the listing hearing this week: - Jushuitan Group Co., Ltd., the largest e-commerce SaaS ERP provider in China, reported revenues of approximately 523 million RMB for 2022 and a loss of about 507 million RMB [30][31] - Fujian Haixi New Drug Creation Co., Ltd., a commercial-stage pharmaceutical company, reported revenues of approximately 212 million RMB for 2022 and a profit of about 69 million RMB [30][31] - Beijing Tongrentang Medical Investment Co., Ltd., the largest non-public Chinese hospital group by market share, reported revenues of approximately 911 million RMB for 2022 and a loss of about 9.23 million RMB [32] - Beijing Yunji Technology Co., Ltd., a robotics service provider, reported revenues of approximately 161 million RMB for 2022 and a loss of about 365 million RMB [32][33] Group 3: New Stocks Listed - Three new stocks were listed on September 30: - Zijin Gold International, which saw a significant increase in market value, surpassing 350 billion HKD [35] - Xipuni, which had an oversubscription rate of 2505.9 times during its public offering [35] - Botai Che Lian, which also experienced a notable increase in stock price [35]

Core Viewpoint - The financial data and operational status disclosed in the prospectus of Puyuan Precision Electric highlight a 14.6% decline in net profit and a 30.5% R&D investment ratio, indicating both challenges and opportunities for the company [1]. Business and Financial Status - Puyuan Precision Electric focuses on the electronic measurement instrument sector, offering a wide range of products including digital oscilloscopes and microwave RF instruments, serving over 100,000 end customers across more than 90 countries and regions, and covering multiple fields such as communication and new energy [2]. - The company emphasizes original technological innovation and has established a self-developed core technology platform, utilizing a combination of distributor sales and direct sales models [2]. Revenue and Profitability - Revenue has shown steady growth, driven by diverse product channels, while net profit has experienced a decline [3]. - Profitability is affected by significant cost and expense impacts, with gross margin fluctuations primarily driven by cost factors [3]. - Net profit margin varies with profitability fluctuations, influenced by multiple factors [3]. Risks and Challenges - Potential risks from related party transactions exist, as the company occasionally engages in transactions with related parties, which may raise questions about the fairness of transaction prices and the impact of changes in related party relationships on business [3]. - The absence of detailed industry comparisons in the prospectus makes it difficult to assess the company's competitive position, although its revenue and net profit growth suggest a certain level of market competitiveness [4]. - Continuous increases in R&D investment and cost pressures are challenges that the industry as a whole faces, necessitating further attention to the company's comparative advantages in technological innovation and cost control [4]. Customer and Supplier Risks - Customer concentration risk exists, with specific customers contributing over 10% of total revenue; for instance, Customer A generated 79.193 million yuan in 2024, and Customer B contributed 40.953 million yuan in the first half of 2025 [5]. - While customer concentration is relatively low, the loss or reduction of orders from major customers could still impact revenue [5]. - The prospectus lacks information on major suppliers and supplier concentration, making it difficult to assess the company's dependency on suppliers and potential risks such as supply interruptions or price fluctuations [6]. Corporate Governance and Management - The controlling shareholder, Dr. Wang Yue, holds approximately 61.01% of the voting rights, which may lead to significant influence over company decisions, posing risks if decisions are made incorrectly [7]. - The management team is experienced, but the effectiveness of their incentives remains to be observed [8]. - The company faces multiple risks, including declining net profit, increased R&D investment, cost and debt pressures, and various risk factors that could challenge future development [8].

Core Viewpoint - The company has submitted an application for the issuance of overseas listed shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange on September 29, 2025 [1] Group 1 - The application was submitted to the Hong Kong Stock Exchange [1] - The application materials were published on the Hong Kong Stock Exchange's website on the same day [1] - The materials were prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1]

Core Viewpoint - Puyuan Precision Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1]. Company Overview - Puyuan Precision is a leading electronic measurement instrument company in China, ranked as the largest by revenue and eighth globally in 2024 according to Frost & Sullivan [4]. - The company offers a comprehensive range of electronic measurement instruments and solutions, serving over 100,000 end customers in more than 90 countries and regions through its "RIGOL" brand [4]. - Puyuan Precision has established a robust product matrix driven by core technology, including digital oscilloscopes, RF instruments, DC precision instruments, and modular instruments [4]. Market Potential - The global test and measurement instrument market is projected to reach approximately RMB 110 billion in 2024, with a compound annual growth rate (CAGR) of 8.6% expected from 2025 to 2029, reaching around RMB 170 billion by 2029 [5]. - In 2024, the top ten companies in the market will include seven overseas firms and three Chinese companies, accounting for about 80.1% of the market share [5]. Financial Performance - Puyuan Precision's revenue for the fiscal years 2022, 2023, and 2024 is reported as approximately RMB 630.57 million, RMB 670.54 million, and RMB 775.83 million, respectively [6]. - The company achieved profits of approximately RMB 92.49 million, RMB 107.95 million, and RMB 92.30 million for the same fiscal years [6]. - For the six months ending June 30, 2024, the revenue was approximately RMB 307.14 million, with a profit of RMB 15.06 million [6].

智通财经APP讯，普源精电(688337.SH)发布公告，公司已于2025年9月29日向香港联合交易所有限公司 (简称"香港联交所")递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请，并于同日在香 港联交所网站刊登了本次发行的申请资料。该申请资料为公司按照香港证券及期货事务监察委员会(简 称"香港证监会")及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修 订。 ...

格隆汇9月29日丨普源精电(688337.SH)公布，公司已于2025年9月29日向香港联合交易所有限公司(以下 简称"香港联交所")递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市(以下简称"本次发行") 的申请，并于同日在香港联交所网站刊登了本次发行的申请资料。 ...

智通财经APP获悉，据港交所9月29日披露，普源精电科技股份有限公司(简称：普源精电(688337.SH))向港交所 主板提交上市申请书，中信证券为独家保荐人。 财务方面，于2022年度、2023年度、2024年度、2024年及2025年截至6月30日止六个月，普源精电实现收益分别 为约6.31亿元、6.71亿元、7.76亿元、3.07亿元、3.55亿元人民币；同期，年/期内利润分别为9248.8万元、约1.08 亿元、9230.3万元、1506.3万元、1621.6万元人民币。 | | | 截至12月31日止年度 | | 截至6月30日止六個月 | | | --- | --- | --- | --- | --- | --- | | | 2022年 | 2023年 | 2024年 | 2024年 | 2025年 | | | | | (人民幣千元) | | | | | | | | (未經濟計) | | | 收益 ... | 630.571 | 670.538 | 775.826 | 307.140 | 354.968 | | 銷售成本 | (309,417) | (312,252) | (349,868) | ...